Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
FAIR Act HR 7953 FDA Modernization
FAIR Act HR 7953 FDA Modernization
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ARPA-H GO via AVIVA STRATEGIES (FKA MGB CONSULTING)
2026 · third_quarter · Q3
- Advanced Research Projects Agency for Health (ARPA-H) FY27 appropriations requests
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACT FOR ULTRA RARE via AVIVA STRATEGIES (FKA MGB CONSULTING)
2026 · third_quarter · Q3
Source: Senate LDA
| HUNTINGTON'S DISEASE SOCIETY OF AMERICA |
| 1 |
| 2025 |
| TAYSHA GENE THERAPIES | 1 | 2025 |
Ultra rare disease advocacy
Filing targets: HOUSE OF REPRESENTATIVES
ENDEAVOR BIOMEDICINES via AVIVA STRATEGIES (FKA MGB CONSULTING)
2026 · third_quarter · Q3
FAIR Act HR 7953 FDA Modernization
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ELEMENT BIOSCIENCES via AVIVA STRATEGIES (FKA MGB CONSULTING)
2026 · third_quarter · Q3
- National Security Commission on Emerging Biotechnology
- Regulatory streamlining - Genomic sequencing - National Biotechnology Initiative Act of 2025
Filing targets: HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE
ARPA-H GO via AVIVA STRATEGIES (FKA MGB CONSULTING)
2026 · second_quarter · Q2
- Advanced Research Projects Agency for Health (ARPA-H) FY27 appropriations requests
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACT FOR ULTRA RARE via AVIVA STRATEGIES (FKA MGB CONSULTING)
2026 · second_quarter · Q2
Ultra rare disease advocacy
Filing targets: HOUSE OF REPRESENTATIVES
ENDEAVOR BIOMEDICINES via AVIVA STRATEGIES (FKA MGB CONSULTING)
2026 · second_quarter · Q2
FAIR Act HR 7953 FDA Modernization
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ELEMENT BIOSCIENCES via AVIVA STRATEGIES (FKA MGB CONSULTING)
2026 · second_quarter · Q2
- Regulatory streamlining - Genomic sequencing - National Biotechnology Initiative Act of 2025
- National Security Commission on Emerging Biotechnology
Filing targets: HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE
ARPA-H GO via AVIVA STRATEGIES (FKA MGB CONSULTING)
2026 · first_quarter · Q1
- Advanced Research Projects Agency for Health (ARPA-H) FY27 appropriations requests
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARPA-H GO via AVIVA STRATEGIES (FKA MGB CONSULTING)
2026 · first_quarter · RR
-Advocating for the funding and independence of the Advanced Research Projects Agency for Health (ARPA-H) - FY27 appropriations
ULTRAGENYX PHARMACEUTICAL via AVIVA STRATEGIES (FKA MGB CONSULTING)
2026 · first_quarter · 1T
n/a termination report
ACT FOR ULTRA RARE via AVIVA STRATEGIES (FKA MGB CONSULTING)
2026 · first_quarter · Q1
Ultra rare disease advocacy
Filing targets: HOUSE OF REPRESENTATIVES
ELEMENT BIOSCIENCES via AVIVA STRATEGIES (FKA MGB CONSULTING)
2026 · first_quarter · Q1
- Regulatory streamlining - Genomic sequencing - National Biotechnology Initiative Act of 2025
- National Security Commission on Emerging Biotechnology
Filing targets: HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE
ACT FOR ULTRA RARE via AVIVA STRATEGIES (FKA MGB CONSULTING)
2026 · first_quarter · RR
Ultra rare disease advocacy
ENDEAVOR BIOMEDICINES via AVIVA STRATEGIES (FKA MGB CONSULTING)
2026 · first_quarter · Q1
FAIR Act FDA Modernization
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
HUNTINGTON'S DISEASE SOCIETY OF AMERICA via AVIVA STRATEGIES (FKA MGB CONSULTING)
2025 · fourth_quarter · RR
Huntington's disease advocacy
BEAM THERAPEUTICS via AVIVA STRATEGIES (FKA MGB CONSULTING)
2025 · fourth_quarter · Q4
-cell and gene therapy policy
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ULTRAGENYX PHARMACEUTICAL via AVIVA STRATEGIES (FKA MGB CONSULTING)
2025 · fourth_quarter · Q4
- ultrarare disease - newborn screening - pediatric priority review voucher
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ENDEAVOR BIOMEDICINES via AVIVA STRATEGIES (FKA MGB CONSULTING)
2025 · fourth_quarter · Q4
FAIR Act FDA Modernization
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ELEMENT BIOSCIENCES via AVIVA STRATEGIES (FKA MGB CONSULTING)
2025 · fourth_quarter · Q4
- Regulatory streamlining - Genomic sequencing - National Biotechnology Initiative Act of 2025
- National Security Commission on Emerging Biotechnology
Filing targets: HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE
TAYSHA GENE THERAPIES via AVIVA STRATEGIES (FKA MGB CONSULTING)
2025 · fourth_quarter · RR
Health insurance reform, affordability of medicines, biotech innovation
BEAM THERAPEUTICS via AVIVA STRATEGIES (FKA MGB CONSULTING)
2025 · third_quarter · Q3
-cell and gene therapy policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ULTRAGENYX PHARMACEUTICAL via AVIVA STRATEGIES (FKA MGB CONSULTING)
2025 · third_quarter · Q3
- ultrarare disease - newborn screening - pediatric priority review voucher
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDEAVOR BIOMEDICINES via AVIVA STRATEGIES (FKA MGB CONSULTING)
2025 · third_quarter · Q3
RESULT Act FDA Modernization
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ELEMENT BIOSCIENCES via AVIVA STRATEGIES (FKA MGB CONSULTING)
2025 · third_quarter · Q3
- Regulatory streamlining - Genomic sequencing - National Biotechnology Initiative Act of 2025
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEAM THERAPEUTICS via AVIVA STRATEGIES (FKA MGB CONSULTING)
2025 · second_quarter · Q2
-cell and gene therapy policy
ULTRAGENYX PHARMACEUTICAL via AVIVA STRATEGIES (FKA MGB CONSULTING)
2025 · second_quarter · Q2
- ultrarare disease - newborn screening
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDEAVOR BIOMEDICINES via AVIVA STRATEGIES (FKA MGB CONSULTING)
2025 · second_quarter · Q2
RESULT Act FDA Modernization
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELEMENT BIOSCIENCES via AVIVA STRATEGIES (FKA MGB CONSULTING)
2025 · second_quarter · Q2
- Regulatory streamlining - Genomic sequencing - National Biotechnology Initiative Act of 2025
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEAM THERAPEUTICS via AVIVA STRATEGIES (FKA MGB CONSULTING)
2025 · second_quarter · RR
- Funding for research - CMS - FDA & regulatory reform
ULTRAGENYX PHARMACEUTICAL via AVIVA STRATEGIES (FKA MGB CONSULTING)
2025 · second_quarter · RR
Rare & ultra-rare disease policy issues, newborn screening, genomic sequencing
ENDEAVOR BIOMEDICINES via AVIVA STRATEGIES (FKA MGB CONSULTING)
2025 · first_quarter · Q1
RESULT Act FDA Modernization
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDEAVOR BIOMEDICINES via AVIVA STRATEGIES (FKA MGB CONSULTING)
2025 · second_quarter · RR
Regulatory reform
ELEMENT BIOSCIENCES via AVIVA STRATEGIES (FKA MGB CONSULTING)
2025 · first_quarter · RR
Regulatory reform